» Articles » PMID: 19901984

Potent Inhibition of HIV-1 Replication by a Tat Mutant

Overview
Journal PLoS One
Date 2009 Nov 11
PMID 19901984
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Herein we describe a mutant of the two-exon HIV-1 Tat protein, termed Nullbasic, that potently inhibits multiple steps of the HIV-1 replication cycle. Nullbasic was created by replacing the entire arginine-rich basic domain of wild type Tat with glycine/alanine residues. Like similarly mutated one-exon Tat mutants, Nullbasic exhibited transdominant negative effects on Tat-dependent transactivation. However, unlike previously reported mutants, we discovered that Nullbasic also strongly suppressed the expression of unspliced and singly-spliced viral mRNA, an activity likely caused by redistribution and thus functional inhibition of HIV-1 Rev. Furthermore, HIV-1 virion particles produced by cells expressing Nullbasic had severely reduced infectivity, a defect attributable to a reduced ability of the virions to undergo reverse transcription. Combination of these inhibitory effects on transactivation, Rev-dependent mRNA transport and reverse transcription meant that permissive cells constitutively expressing Nullbasic were highly resistant to a spreading infection by HIV-1. Nullbasic and its activities thus provide potential insights into the development of potent antiviral therapeutics that target multiple stages of HIV-1 infection.

Citing Articles

Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV.

Bowden-Reid E, Moles E, Kelleher A, Ahlenstiel C Drug Deliv Transl Res. 2025; .

PMID: 39833468 DOI: 10.1007/s13346-025-01788-x.


Enhanced NF-κB activation via HIV-1 Tat-TRAF6 cross-talk.

Li Y, Liu X, Fujinaga K, Gross J, Frankel A Sci Adv. 2024; 10(3):eadi4162.

PMID: 38241362 PMC: 10798561. DOI: 10.1126/sciadv.adi4162.


Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure.

Duggan N, Dragic T, Chanda S, Pache L Viruses. 2023; 15(12).

PMID: 38140676 PMC: 10747579. DOI: 10.3390/v15122435.


Sulforaphane prevents the reactivation of HIV-1 by suppressing NFκB signaling.

Jamal I, Paudel A, Thompson L, Abdelmalek M, Khan I, Singh V J Virus Erad. 2023; 9(3):100341.

PMID: 37663574 PMC: 10469555. DOI: 10.1016/j.jve.2023.100341.


GigaAssay - An adaptable high-throughput saturation mutagenesis assay platform.

Benjamin R, Giacoletto C, FitzHugh Z, Eames D, Buczek L, Wu X Genomics. 2022; 114(4):110439.

PMID: 35905834 PMC: 9420302. DOI: 10.1016/j.ygeno.2022.110439.


References
1.
HAUBER J, Malim M, Cullen B . Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol. 1989; 63(3):1181-7. PMC: 247813. DOI: 10.1128/JVI.63.3.1181-1187.1989. View

2.
Modesti N, Garcia J, Debouck C, Peterlin M, Gaynor R . Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol. 1991; 3(8):759-68. View

3.
Echetebu C, Rhim H, Herrmann C, Rice A . Construction and characterization of a potent HIV-2 Tat transdominant mutant protein. J Acquir Immune Defic Syndr (1988). 1994; 7(7):655-64. View

4.
Stauber R, Gaitanaris G, Pavlakis G . Analysis of trafficking of Rev and transdominant Rev proteins in living cells using green fluorescent protein fusions: transdominant Rev blocks the export of Rev from the nucleus to the cytoplasm. Virology. 1995; 213(2):439-49. DOI: 10.1006/viro.1995.0016. View

5.
Dayton A, Sodroski J, Rosen C, Goh W, Haseltine W . The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell. 1986; 44(6):941-7. DOI: 10.1016/0092-8674(86)90017-6. View